Vivek Narayan is an Oncology physician affiliated with University of Pennsylvania. OpenAlex indexes 313 publications with 4,002 citations (h-index 32); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3400 Civic Center Blvd Fl 3
Philadelphia, PA 191045127
Telephone
215-615-5858Registry record last updated 20 Sept 2019.
Clinical trials
- 211At-MABG in Adults With Advanced Neuroendocrine Cancers
Sponsor: University of Pennsylvania
- Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
Sponsor: Abramson Cancer Center at Penn Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Sumitomo Pharma America, Inc.Program year20253 payments
- PFIZER INC.Program year20254 payments
- Exelixis Inc.Program year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
80.7%Androgen Receptor Inhibitor34.4%Xtandi81%Bicalutamide19%Part D≥23 patientsKinase inhibitor20.8%Cabometyx48%Lenvima33%Inlyta19%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
15.4%Corticosteroid12.6%Prednisone100%Part D≥18 patientsPotassium supplement2.8%Klor-Con M20100%Part D<11 patientsHormonal (systemic)
3.9%l-Thyroxine3.9%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2026 per NIH RePORTER. The latest:
- Early phase clinical trials of 211At-meta-astatobenzylguanidine for children with neuroblastoma and adults with advanced neuroendocrine cancers
University of Pennsylvania
FY2026$679,710R01CA300202 - Early phase clinical trials of 211At-meta-astatobenzylguanidine for children with neuroblastoma and adults with advanced neuroendocrine cancers
University of Pennsylvania
FY2025$695,205R01CA300202
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Harold Feldman, MD
University of Pennsylvania
Howard Herrmann, MD
University of Pennsylvania
Robert Vonderheide, MD
University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”